BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Bio-Thera Solutions readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Bio-Thera Solutions's drugs run\,
  from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06094179-1438@assetmemo.bio
DTSTAMP:20261121T005638Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Vedastotug: Phase 1/2 readout est. (NCT06094179)
DESCRIPTION:Vedastotug\, phase 1/2\, Atopic Dermatitis.\nStudy: Evaluate th
 e Safety\, Tolerability of BAT6026\nEstimated primary completion: 31 Decem
 ber 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/vedastotug#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0609
 4179
URL:https://assetmemo.bio/drug/vedastotug#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07515079-4969@assetmemo.bio
DTSTAMP:20261121T005638Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:BAT5906: Phase 3 readout est. (NCT07515079)
DESCRIPTION:BAT5906\, phase 3.\nStudy: Efficacy Evaluation Study of BAT5906
  and Lucentis® in Patients With Diabetic Macular Edema\nEstimated primary
  completion: 30 April 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/bat5906#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07515079
URL:https://assetmemo.bio/drug/bat5906#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
